Compare CVV & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | BCTX |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 18.5M |
| IPO Year | N/A | N/A |
| Metric | CVV | BCTX |
|---|---|---|
| Price | $3.32 | $9.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 17.7K | ★ 57.6K |
| Earning Date | 11-10-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,251,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $2.46 | $6.00 |
| 52 Week High | $4.80 | $106.50 |
| Indicator | CVV | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 44.95 |
| Support Level | $3.15 | $11.38 |
| Resistance Level | $3.40 | $13.09 |
| Average True Range (ATR) | 0.19 | 1.14 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 42.63 | 30.12 |
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.